

Inventor(s): Papadopoulos et al

Appln. No.: 09

Series Code ↑


762,594

Serial No. ↑

Filed: February 9, 2001

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Group Art Unit Unassigned

Examiner Unassigned

Atty. Dkt. P 277848 82137

M# Client Ref

Appln. Title: Peripheral-Type Benzodiazepine Receptor Associated Proteins, Cloning, Expression and Methods of Use

Date: September 10, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

A. NOT made B. Withdrawn
 C. made herewith D. made previously
 } For B & C
 See Required
 Separate Paper
 (Pat-256)

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus	20	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus	0	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)	add		+ \$270/\$135 =	+ \$0		104/204
5. Original due Date: <input type="checkbox"/> NONE						
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo) (2 mos) (3 mos) (Usable only for ≤ 2mo.OA --- 4 mos) (Usable only for 30 day/1mo.OA --- 5 mos)	\$110/\$55 = \$390/\$195 = \$890/\$445 = \$1390/\$695= \$1890/\$945=	+ \$0			115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract		- \$0				
8.			Extension Fee Attached		+ \$0	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee		+ \$110/\$55	+ \$0			148/248
10. If IDS attached requires Official Fee under Rule 97 (c), or if Rule 97(d) Request	add add	+ \$180 + \$180	+ \$0			126 126
11. After-Final Request Fee per rules 129(a) and 17(r)		+ \$710/355	+ \$0			146/246
12. No. of additional inventions for examination per Rule 129(b)		x \$710/355 ea	+ \$0			149/249
13. Request for Continued Examination (RCE)		+ \$710/355	+ \$0			1179/1279
14. Petition fee for		+ \$0				
15.		TOTAL FEE ENCLOSED =	\$0			

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975

(Our Order No. 82137 277848

C# M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Samir Elamrani

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Atty/Sec: SE/SM

Sig:

Reg. No. 43601

Fax: (703) 905-2500

Tel: (703) 905-2064

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Papadopoulos et al.

Group Art Unit: Unassigned

Application No. 09/762,594

Examiner: Unassigned

Filed: February 9, 2001

Title: Peripheral-Type Benzodiazepine Receptor Associated Proteins, Cloning, Expression
And Methods Of Use

* * * * *

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Official Action dated August 8, 2001 containing a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, attached please find a copy of the "Sequence Listing" in computer readable format along with a printed copy of the sequence listing and a Statement to Support Filing and Submission in Accordance with 37 C.F.R. §1.821-1.825.

Further, it is requested that the specification be amended to place the enclosed Sequenced Listing between pages 52 and 53 of the application.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: Samir Elamrani
Samir Elamrani
Registration No. 43,601

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2000
(703) 905-2500 Facsimile

Date: September 10, 2001

Enclosure: Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures